This article is more than 5 years old. Information may no longer be current.

RegeneRx, Digital Aria sign two product license agreements

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

RegeneRx Biopharmaceuticals and Digital Aria have entered into two product license agreements to develop RegeneRx’s RGN-259 preservative-free eye drop product candidate in Asia and its RGN-137 topical dermal gel product candidate in the U.S., according to a press release.

License terms include commercial milestone payments of up to $7 million and a double-digit royalty on any commercial sales. Digital Aria has to initiate phase 2 clinical trials in the U.S. and Australia within 3 years, the release said.

Digital Aria will make an equity investment of $2.35 million, enabling RegeneRx to proceed with its ophthalmic clinical program, and has a 10-month option to purchase additional common stock for $825,000, the release said.

The agreement, as it pertains to RGN-137, will be exclusive in the U.S., while the terms pertaining to RGN-259 will be exclusive in Korea, Japan, Australia, New Zealand, Brunei, Cambodia, East Timor, Indonesia, Laos, Malaysia, Mongolia, Myanmar (Burma), Philippines, Singapore, Thailand, Vietnam and Kazakhstan.

Additionally, RGN-259 will be semi-exclusive in India, Pakistan, Bangladesh, Bhutan, Maldives, Nepal, Sri Lanka, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan.